Clinical TrialsThe initiation, enrollment, and dosing of CT-95 in trials are seen positively, especially since it was licensed by the company recently.
Financial PerformanceContext remains well-capitalized with $94.4M in cash, providing financial stability and runway into 2027.
Product DevelopmentContext is preparing to file an IND for CT-202, a potential best-in-class bispecific antibody for various cancers, indicating future growth potential.